Competitor Analysis: Erythropoiesis Stimulating Agents (ESA)

Publisher: La Merie Publishing
Pages: 94
Product Line:
Competitor Analysis
Format: PDF
Product Code: LMCA0034
Release Date: April of 2013

500.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Erythropoiesis Stimulating Agents (ESA)

Product description

The Competitive Intelligence Report Erythropoiesis Stimulating Agents (ESA) as of April 2013 provides information on existing first and second generation epoetin products in regulated markets, an overview on biosimilar versions of erythropoietin (EPO) in regulated markets, a compilation of novel, next generation Erythropoiesis Stimulating Agents (ESAs) separately for biologics and for oral small molecules and a summary of first generation EPO products as well as of darbepoietin biosimilar versions in less regulated markets.

Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently marketed Erythropoieitin (EPO) & Erythropoiesis Stimulating Agents (ESA) products and active EPO and ESA projects in research and development. In addition, the report lists company-specific product portfolios and R&D pipelines of Erythropoietin (EPO) & Erythropoiesis Stimulating Agents (ESA) on the market or in R&D. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Erythropoiesis Stimulating Agents (ESA)

Table of Contents

  • First generation epoetins in regulated markets
  • Second generation epoetins in regulated markets
  • Epoetin biosimilars in regulated markets
  • Darbepoetin biosimilars in regulated markets
  • Next generation biologic Eythropoiesis Stimulating Agents (ESA) in regulated markets
  • Next generation small molecule Erythropoiesis Stimulating Agents
  • First generation EPO in less regulated markets (Central & South America; Africa; Asia; Rest of the World)
  • Darbepoietin biosimilars in less regulated markets
  • Next generation biologic Erythropoiesis Stimulating Agents (ESA) in less regulated markets
  • About La Merie



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up